BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

157

508869

APOLLOHOSP

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

APOLLO HOSPITALS ENTER. L performance

Today’s low

Today’s high

₹ 6920.00 ₹ 7035.50
₹ 6977.00

52 week low

52 week high

₹ 5693.20 ₹ 7545.35
₹ 6977.00

Open Price

₹ 6992.00

Prev. Close

₹ 6992.50

Volume (Shares)

499567.00

Total traded value

₹ 34854.78

Upper Circuit

₹ 7691.50

Lower Circuit

₹ 6293.50

info

APOLLO HOSPITALS ENTER. L Share Price Update

As of the latest trading session, APOLLO HOSPITALS ENTER. L share price is currently at ₹ 6977, which is down by ₹ -15.50 from its previous closing. Today, the stock has fluctuated between ₹ 6920.00 and ₹ 7035.50. Over the past year, APOLLO HOSPITALS ENTER. L has achieved a return of 17.31 %. In the last month alone, the return has been 5.19 %. Read More...

APOLLO HOSPITALS ENTER. L fundamentals


  • Market cap (Cr)

    1,00,318.60

  • P/E Ratio (TTM)

    83.30

  • Beta

    0.50

  • Book Value / share

    569.62

  • Return on equity

    13.81%

  • EPS (TTM)

    83.58

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    341.60

info icon alternate text
  • Market cap (Cr)

    99,988.56

  • P/E Ratio (TTM)

    83.30

  • Beta

    0.48

  • Book Value / share

    569.62

  • Return on equity

    13.81%

  • EPS (TTM)

    83.58

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    341.60

info icon alternate text

APOLLO HOSPITALS ENTER. L Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 2054.80
Operating Expense 1713.40
Net Profit 341.60
Net Profit Margin (%) 16.62
Earnings Per Share (EPS) 23.76
EBITDA 619.70
Effective Tax Rate (%) 23.97
Particulars SEP 2024 (Values in Cr)
Revenue 2135.40
Operating Expense 1768.80
Net Profit 369.60
Net Profit Margin (%) 17.30
Earnings Per Share (EPS) 25.71
EBITDA 661.19
Effective Tax Rate (%) 24.18
Particulars JUN 2024 (Values in Cr)
Revenue 1936.60
Operating Expense 1632.20
Net Profit 251.70
Net Profit Margin (%) 12.99
Earnings Per Share (EPS) 17.51
EBITDA 498.10
Effective Tax Rate (%) 24.11
Particulars MAR 2024 (Values in Cr)
Revenue 1894.60
Operating Expense 1628.20
Net Profit 238.80
Net Profit Margin (%) 12.60
Earnings Per Share (EPS) 16.61
EBITDA 496.40
Effective Tax Rate (%) 23.55
Particulars DEC 2023 (Values in Cr)
Revenue 1824.30
Operating Expense 1531.80
Net Profit 262.80
Net Profit Margin (%) 14.40
Earnings Per Share (EPS) 18.28
EBITDA 501.80
Effective Tax Rate (%) 23.60
Particulars MAR 2024 (Values in Cr)
Book Value / Share 481.75
ROE % 13.98
ROCE % 15.37
Total Debt to Total Equity 0.74
EBITDA Margin 13.11
Particulars MAR 2023 (Values in Cr)
Book Value / Share 430.43
ROE % 15.04
ROCE % 14.16
Total Debt to Total Equity 0.71
EBITDA Margin 12.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 390.51
ROE % 17.26
ROCE % 16.67
Total Debt to Total Equity 0.81
EBITDA Margin 15.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 319.52
ROE % 2.41
ROCE % 6.47
Total Debt to Total Equity 0.98
EBITDA Margin 11.15
Particulars MAR 2020 (Values in Cr)
Book Value / Share 239.32
ROE % 9.20
ROCE % 11.88
Total Debt to Total Equity 1.09
EBITDA Margin 14.38
Particulars MAR 2024 (Values in Cr)
Book Value / Share 536.22
ROE % 13.81
ROCE % 15.48
Total Debt to Total Equity 0.39
EBITDA Margin 27.19
Particulars MAR 2023 (Values in Cr)
Book Value / Share 481.56
ROE % 16.64
ROCE % 16.00
Total Debt to Total Equity 0.40
EBITDA Margin 28.09
Particulars MAR 2022 (Values in Cr)
Book Value / Share 424.94
ROE % 11.56
ROCE % 12.62
Total Debt to Total Equity 0.51
EBITDA Margin 23.68
Particulars MAR 2021 (Values in Cr)
Book Value / Share 361.72
ROE % 2.29
ROCE % 5.12
Total Debt to Total Equity 0.68
EBITDA Margin 18.31
Particulars MAR 2020 (Values in Cr)
Book Value / Share 286.52
ROE % 9.10
ROCE % 12.05
Total Debt to Total Equity 0.81
EBITDA Margin 14.58
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 933.80
Total Assets 16753.10
Total Liabilities 16753.10
Total Equity 7320.50
Share Outstanding 143784657
Price to Book Ratio 11.85
Return on Assets (%) 5.36
Return on Capital (%) 8.57
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 775.80
Total Assets 14427.80
Total Liabilities 14427.80
Total Equity 6531.30
Share Outstanding 143784657
Price to Book Ratio 8.95
Return on Assets (%) 5.67
Return on Capital (%) 8.86
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 924.00
Total Assets 13269.30
Total Liabilities 13269.30
Total Equity 5903.00
Share Outstanding 143784657
Price to Book Ratio 10.63
Return on Assets (%) 7.95
Return on Capital (%) 12.36
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 724.40
Total Assets 11416.70
Total Liabilities 11416.70
Total Equity 4802.40
Share Outstanding 143784657
Price to Book Ratio 8.03
Return on Assets (%) 1.31
Return on Capital (%) 1.96
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 466.80
Total Assets 11338.40
Total Liabilities 11338.40
Total Equity 3469.80
Share Outstanding 139125160
Price to Book Ratio 3.97
Return on Assets (%) 4.01
Return on Capital (%) 6.67
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 342.20
Total Assets 12405.20
Total Liabilities 12405.20
Total Equity 7710.90
Share Outstanding 143784657
Price to Book Ratio 11.85
Return on Assets (%) 8.14
Return on Capital (%) 10.45
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 318.00
Total Assets 10780.40
Total Liabilities 10780.40
Total Equity 6924.80
Share Outstanding 143784657
Price to Book Ratio 8.95
Return on Assets (%) 10.06
Return on Capital (%) 12.49
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 556.90
Total Assets 10408.20
Total Liabilities 10408.20
Total Equity 6110.70
Share Outstanding 143784657
Price to Book Ratio 10.63
Return on Assets (%) 6.39
Return on Capital (%) 8.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 408.20
Total Assets 9729.20
Total Liabilities 9729.20
Total Equity 5201.50
Share Outstanding 143784657
Price to Book Ratio 8.03
Return on Assets (%) 1.07
Return on Capital (%) 1.4
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 346.50
Total Assets 10144.20
Total Liabilities 10144.20
Total Equity 3988.40
Share Outstanding 139125160
Price to Book Ratio 3.97
Return on Assets (%) 4.63
Return on Capital (%) 6.77
Particulars MAR 2024 (Values in Cr)
Net Income 935.00
Cash from Operations 2386.90
Cash from Investing -1537.20
Cash from Financing -311.00
Net change in Cash 72.00
Free Cash Flow 3523.70
Particulars MAR 2023 (Values in Cr)
Net Income 844.30
Cash from Operations 1758.90
Cash from Investing -870.60
Cash from Financing -633.20
Net change in Cash -126.90
Free Cash Flow 2887.40
Particulars MAR 2022 (Values in Cr)
Net Income 1108.40
Cash from Operations 1900.30
Cash from Investing -847.20
Cash from Financing -791.60
Net change in Cash 57.20
Free Cash Flow 2557.50
Particulars MAR 2021 (Values in Cr)
Net Income 136.80
Cash from Operations 1229.30
Cash from Investing -863.40
Cash from Financing -340.10
Net change in Cash 61.10
Free Cash Flow 1524.80
Particulars MAR 2020 (Values in Cr)
Net Income 431.70
Cash from Operations 1598.90
Cash from Investing -288.80
Cash from Financing -909.60
Net change in Cash 94.50
Free Cash Flow 2111.90
Particulars MAR 2024 (Values in Cr)
Net Income 1010.50
Cash from Operations 1521.40
Cash from Investing -835.30
Cash from Financing -297.00
Net change in Cash 59.10
Free Cash Flow 2142.40
Particulars MAR 2023 (Values in Cr)
Net Income 1084.80
Cash from Operations 1547.90
Cash from Investing -588.50
Cash from Financing -778.60
Net change in Cash -142.60
Free Cash Flow 1943.90
Particulars MAR 2022 (Values in Cr)
Net Income 665.20
Cash from Operations 1299.40
Cash from Investing -505.30
Cash from Financing -576.60
Net change in Cash 119.00
Free Cash Flow 1823.00
Particulars MAR 2021 (Values in Cr)
Net Income 105.00
Cash from Operations 911.70
Cash from Investing -764.70
Cash from Financing -175.60
Net change in Cash -24.80
Free Cash Flow 1105.90
Particulars MAR 2020 (Values in Cr)
Net Income 470.30
Cash from Operations 1347.00
Cash from Investing -263.90
Cash from Financing -770.70
Net change in Cash 61.50
Free Cash Flow 1784.70
Company Name Price P/E P/B Market Cap 52 Week Low/High
FORTIS MALAR HOSPITALS LIMITED 75.38 183.85 4.73 141.28 51.01 / 98.70
SHREE PACETRONIX LTD. 70.00 14.58 1.87 25.20 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.68 0.00 2.57 27.88 3.22 / 10.84
VIMTA LABS LIMITED 1000.45 36.59 6.48 2224.45 420.00 / 1183.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 32.25 0.00 -17.27 24.09 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5560.50 29.47 6.24 6083.19 3750.00 / 6400.00
FORTIS MALAR HOSPITALS LIMITED 75.38 54.23 4.77 141.28 51.01 / 98.70

APOLLO HOSPITALS ENTER. L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
6977.00 -0.22 redarrow
red-green-graph indicator
6 Bearish
10 Bullish
  • 5 Days 7012.70
  • 26 Days 6838.80
  • 10 Days 6996.10
  • 50 Days 6742.30
  • 12 Days 6977.90
  • 100 Days 6739.30
  • 20 Days 6892.40
  • 200 Days 6655.60
7019.50 PIVOT

First Support

6949.00

First Resistance

7063.00

Second Support

6905.50

Second Resistance

7133.50

Third Support

6835.00

Third Resistance

7177.00

RSI

58.00

ADX

42.71

MACD

139.06

Williams % R

-46.02

Commodity Channel Index (CCI)

35.03

Date

2025-04-30

Week

231897.00

Same Day

367289.00

Month

299345.00

1 Year

0.50

3 Year

0.66

Over 1 Month

5.19%

down

Over 1 Year

17.31%

down

Over 3 Months

2.23%

down

Over 3 Years

17.46%

down

Over 6 Months

-0.07%

down

Over 5 Years

37.99%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

APOLLO HOSPITALS ENTER. L shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
5.63%
Promoter Holdings
29.33%
FII
42.73%
DII
22.28%
Promoter Shares(Pledge Percentage)
13.47%
Name Shares Category
M/s. Pcr Investments Ltd 2.7223124E7 (18.93%) Shareholding of Promoter and Promoter Group
Life Insurance Corporation Of India 5419226.0 (3.77%) Public Shareholding
Ms. Suneeta Reddy 4834305.0 (3.36%) Shareholding of Promoter and Promoter Group
Hdfc Trustee Company Limited 3421976.0 (2.38%) Public Shareholding
Mirae Asset Elss Tax Saver Fund 2703529.0 (1.88%) Public Shareholding
Government Of Singapore 2537036.0 (1.76%) Public Shareholding
Ms. Sangita Reddy 2432508.0 (1.69%) Shareholding of Promoter and Promoter Group
Ms. Shobana Kamineni 2239952.0 (1.56%) Shareholding of Promoter and Promoter Group
Sbi Nifty 50 Etf 2034435.0 (1.41%) Public Shareholding
Axis Mutual Fund Trustee Limited 1762780.0 (1.23%) Public Shareholding
Schroder International Selection Fund Asian Opportunities 1677461.0 (1.17%) Public Shareholding
Government Pension Fund Global 1617981.0 (1.13%) Public Shareholding
Mr. K Vishweshwar Reddy 1577350.0 (1.1%) Shareholding of Promoter and Promoter Group
Kotak Funds - India Midcap Fund 1540000.0 (1.07%) Public Shareholding
Franklin India Flexi Cap Fund 1531276.0 (1.06%) Public Shareholding
Nippon Life India Trustee Ltd 1490267.0 (1.04%) Public Shareholding
Ms. Preetha Reddy 1043915.0 (0.73%) Shareholding of Promoter and Promoter Group
Mr. Karthik Anand 346167.0 (0.24%) Shareholding of Promoter and Promoter Group
Mr. Harshad Reddy 327900.0 (0.23%) Shareholding of Promoter and Promoter Group
Ms. Sindoori Reddy 318600.0 (0.22%) Shareholding of Promoter and Promoter Group
Ms. Anuspala Kamineni 259174.0 (0.18%) Shareholding of Promoter and Promoter Group
Dr. Prathap C Reddy 245464.0 (0.17%) Shareholding of Promoter and Promoter Group
Mr. Konda Anindith Reddy 230200.0 (0.16%) Shareholding of Promoter and Promoter Group
Mr. Puansh Kamineni 212201.0 (0.15%) Shareholding of Promoter and Promoter Group
Ms. Upasana Konidela 217276.0 (0.15%) Shareholding of Promoter and Promoter Group
Mr. Konda Vishwajit Reddy 222300.0 (0.15%) Shareholding of Promoter and Promoter Group
Mr. Konda Viraj Madhav Reddy 168224.0 (0.12%) Shareholding of Promoter and Promoter Group
Ms. Sucharitha P Reddy 169800.0 (0.12%) Shareholding of Promoter and Promoter Group
M/s. Indian Hospitals Corporation Ltd 61704.0 (0.04%) Shareholding of Promoter and Promoter Group
Mr. Dwaraknath Reddy 18000.0 (0.01%) Shareholding of Promoter and Promoter Group
Mr. Vijay Kumar Reddy 8957.0 (0.01%) Shareholding of Promoter and Promoter Group
Mr. Aditya Reddy 10200.0 (0.01%) Shareholding of Promoter and Promoter Group
M/s. Obul Reddy Investments Pvt Ltd 11200.0 (0.01%) Shareholding of Promoter and Promoter Group
Mr. Anil Kamineni 20.0 (0.0%) Shareholding of Promoter and Promoter Group
M/s. Ppn Power Generating Company Private Ltd 4500.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

APOLLO HOSPITALS ENTER. L corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Feb 2024 6.0 Interim 20 Feb 2024 Equity shares
18 Aug 2023 9.0 Final 19 Aug 2023 Equity shares
24 Feb 2023 6.0 Interim 24 Feb 2023 Equity shares
18 Aug 2022 11.75 Final 20 Aug 2022 Equity shares
18 Aug 2021 3.0 Final 21 Aug 2021 Equity shares
17 Sep 2020 2.75 Final 19 Sep 2020 Equity shares
25 Feb 2020 3.25 Interim 26 Feb 2020 Equity shares
12 Sep 2019 6.0 Final 14 Sep 2019 Equity shares
12 Sep 2018 5.0 Final 15 Sep 2018 Equity shares
07 Sep 2017 6.0 Final 09 Sep 2017 Equity shares
22 Mar 2016 6.0 Interim 23 Mar 2016 Equity shares
30 Jul 2015 5.75 Final 01 Aug 2015 Equity shares
13 Aug 2014 5.75 Final 19 Aug 2014 Equity shares
25 Jul 2013 5.5 Final 27 Jul 2013 Equity shares
26 Jul 2012 4.0 Final 28 Jul 2012 Equity shares
07 Jul 2011 3.75 Final 09 Jul 2011 Equity shares
15 Jul 2010 7.0 Final 17 Jul 2010 Equity shares
20 Aug 2009 6.5 Final 22 Aug 2009 Equity shares
11 Aug 2008 6.0 Final 13 Aug 2008 Equity shares
09 Aug 2007 2.0 Final 11 Aug 2007 Equity shares
22 Mar 2007 3.0 Interim 24 Mar 2007 Equity shares
29 Jul 2005 0.0 Final 02 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
02 Sep 2010 10.0 5.0 03 Sep 2010
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Feb 2024 6.0 Interim 20 Feb 2024 Equity shares
18 Aug 2023 9.0 Final 19 Aug 2023 Equity shares
24 Feb 2023 6.0 Interim 24 Feb 2023 Equity shares
18 Aug 2022 11.75 Final 20 Aug 2022 Equity shares
18 Aug 2021 3.0 Final 21 Aug 2021 Equity shares
17 Sep 2020 2.75 Final 19 Sep 2020 Equity shares
25 Feb 2020 3.25 Interim 26 Feb 2020 Equity shares
12 Sep 2019 6.0 Final 14 Sep 2019 Equity shares
12 Sep 2018 5.0 Final 15 Sep 2018 Equity shares
07 Sep 2017 6.0 Final 09 Sep 2017 Equity shares
22 Mar 2016 6.0 Interim 23 Mar 2016 Equity shares
30 Jul 2015 5.75 Final 01 Aug 2015 Equity shares
13 Aug 2014 5.75 Final 19 Aug 2014 Equity shares
25 Jul 2013 5.5 Final 27 Jul 2013 Equity shares
26 Jul 2012 4.0 Final 28 Jul 2012 Equity shares
07 Jul 2011 3.75 Final 09 Jul 2011 Equity shares
15 Jul 2010 7.0 Final 17 Jul 2010 Equity shares
20 Aug 2009 6.5 Final 22 Aug 2009 Equity shares
11 Aug 2008 6.0 Final 13 Aug 2008 Equity shares
09 Aug 2007 2.0 Final 11 Aug 2007 Equity shares
22 Mar 2007 3.0 Interim 24 Mar 2007 Equity shares
29 Jul 2005 0.0 Final 02 Aug 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
02 Sep 2010 10.0 5.0 03 Sep 2010

Apollo Hospitals Enterprise Limited Overview

Apollo Hospitals, founded in 1983 by Dr. Prathap C Reddy, marked the advent of the corporate hospital model in India, leading the private healthcare revolution. It has since established itself as Asia’s leading integrated healthcare services provider, with an extensive presence across the healthcare spectrum, including hospitals, pharmacies, primary care, diagnostic clinics, and various retail health models. As of Q1FY24, Apollo boasts 43 owned and 6 managed hospitals across major urban centres, including Chennai and Hyderabad, offering over 9,500 beds, achieving an occupancy rate of 62%, and an average revenue per occupied bed (ARPOB) of Rs. 57,760. The diagnostics and retail health segment further includes 22 ambulatory care & birthing centres, over 2,000 diagnostics centres, and more than 120 dialysis centres. The digital health and pharmacy distribution network encompasses over 5,600 outlets, with significant growth in the last fiscal year, contributing to a 41% share of the company’s revenue. Notably, Apollo has achieved global recognition in solid multi-organ transplantation, leading with over 23,000 transplants and expanding its robotic colorectal surgery program. The revenue distribution reflects a significant emphasis on healthcare services, contributing 52%, with diagnostics and retail health and digital health & pharma rounding out the financial ecosystem. This comprehensive approach underlines Apollo Hospitals' commitment to innovating and expanding its services, reinforcing its position as a healthcare leader in India and beyond.
 

Apollo Hospitals Share Result Highlights  

Apollo Hospitals Enterprise Ltd. is an Indian healthcare provider and also happens to be the first corporate hospital in India. The company is a huge player in the healthcare industry and provides various services like medical care, diagnostics, and pharmacy services. As of 21 January 2025, 04:01 pm, Apollo Hospitals share price stood at  ₹6919.15 per share.

Apollo Hospitals Share Annual Reports 

According to their Annual Report 2023-24, Apollo Hospital’s operating income fell by 0.2% YoY while its operating profit grew by 55.7% YoY. The net profit of the company also saw a growth of 61.6% YoY and its net profit margins grew from 13.9% in FY23 to 22.5% in FY24.

Apollo Hospitals Share Dividend

The company announced its last dividend in the quarter ending March 2024. The dividend declared stood at ₹10 which translates to a dividend yield of 0.36%.
 

APOLLO HOSPITALS ENTER. L Share Price

Apollo Hospitals Enterprise Limited (AHEL) is a leading private sector healthcare provider in Asia. It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics. AHEL's Hospitals are situated in Chennai, Hyderabad, Delhi, Ahmedabad, Pune, Chenganur, Coimbatore, Jaipur, Madurai, Anantpur, Nellore, Kurnool, Bhopal, Ranchi, Bilaspur and Bacheli. The main business of the Company is to enhance the quality of life of patients by providing comprehensive, high-quality hospital services on a cost-effective basis and providing / selling high quality pharma and wellness products through a network of pharmacies. The principal activities of the Company include operation of multidisciplinary private hospitals, clinics and pharmacies.

Apollo Hospitals Enterprise Limited was incorporated as a Public Limited Company on December 5, 1979, a comprehensive 250-bed hospital with an emphasis on speciality and super specialties in over fifty departments at Chennai. Dr. Prathap C. Reddy promoted it. 46 beds were added in the year 1985. It is the first group of hospitals that pioneered the concept of corporate healthcare delivery in India.

The Apollo Health Association (AHA) was inaugurated in April of the year 1986, based on credit card system. As per this scheme, the Apollo health insurance policyholders get Medicare offered by Apollo and 76 accredited hospitals in selected cities. The hospital was equipped with Magnetic Resonance Imaging (MRI) during the year 1989, also with SOMATOMCR whole body computed Tomography scanner, Dideoendoscopy and Mammography, breast-scanning equipment for the detection of occult carcinoma. During the same year 1989, AHEL group had finalised a joint venture project with the I.R.T.C. of Eye Micro Surgery, USSR to launch the Apollo Fyodorov Eye Research Institute. Apart from the hospital activities, The Apollo School of nursing was commissioned in August of the year1991, which offers a 3-year diploma programme followed by internship in the hospital.

During the year 1992, 16 intensive care beds and 26 additional patient beds together with balancing equipment were added in various disciplines. Also a 24-hour ambulance service with wireless facility was to be launched. Apollo cancer hospital was commissioned with 150-beds for cancer treatment and research centre in Chennai during the period of 1993. Further, AHEL had introduced state-of-the-art Bone Marrow transplant facility in Phase II expansion of cancer project. A third theater was added for cardio thoracic surgery in the year of 1994. As at 19th February of the year 1995, another one wing was added, Cancer hospital in Hyderabad was inaugurated. In the same year 1995, AHEL had joined hands with the WHO with its mission to eradicate Tuberculosis in India. With takeover of Orient Hospital, Madurai and Pinakini Hospital, Nellore, the Company had added 300 more beds in the year 1996 and the Apollo College of Nursing at Keezhkattalai was inaugurated on 21st October of the same year. AHEL had signed a memorandum of understanding with Jardine of UK for successful adaptation of the health maintenance organisations (HMO) in the year 1997, a concept for the first time in India. A year after, in 1998, also signed a memorandum of understanding with the Sri Lankan Government to build a super-speciality hospital in Colombo. It was the first time the speciality hospital group ventured abroad with investments. AHEL had opened a unit for the Kidney disorders; it was inaugurated in April of the year 1998 with the expansion in this facility for better and newer techniques in treatment.

In 1999, Apollo had launched its first poison information centre in the south of the India. Indian Oil Corporation Ltd (IOCL) and AHEL had signed a memorandum of understanding (MoU) in the year 2000 for setting up pharmaceutical general stores at the convenience stores of Indian Oil petrol stations. Apollo and Royal College of General Practioners made a tie-up in the period of 2000 to launch three programmes for revalidating and updating the knowledge of primary healthcare physicians in India. The company also inked an in-principle deal with the Singapore-based Parkway group, the global leader in healthcare business, to spread its wings to Afro Asian countries. In the same year AHEL had launched a personal accident insurance card and commissioned the Italian Dental Clinic. The amalgamation of Indian Hospitals Corporation (IHCL), Om Sindoori Hotels (OSHL) with the company has been approved; also Deccan Hospital Corporation (DHCL) has been amalgamated with company. In 2001, the company signed a memorandum of understanding with the government of Mauritius, appointing the Apollo Hospitals Group as the preferred healthcare provider for all the citizens of Mauritius and in the identical year, made a tie-up with a local hospital initially to deliver mother and child care.

During the year 2002, the hospital has taken over the 50.26 per cent of stake held by the Gauri Prasad Goenka in the Duncan Gleneagles Hospital for the consideration of Rs 3 crore. In 2003, AHEL made tie up with ICICI Lombard and unveiled an accident insurance product. Apollo launched a dedicated pediatric cardiac facility for children and sets up a 24X7 Chest Pain Clinic to offer round the clock and immediate access to quality heart care during the critical period.

AHEL had entered into a major technology partnership with the Defence Research & Development Organisation (DRDO) to leverage mutual strengths during the period of 2004. Launched the Apollo National Heart Plan' comprising three components of the preventive mode, a disease management programme (DMP) and the actual treatment and surgery component. And also in the same year, it made a partnership to provide advisory services to Hayel Saeed Anam (HSA) group, Yemen. Apollo Hospital Delhi gets JCI certification for its quality of care in a safe environment in the year 2005. In the same year, it forged alliance with Histotem and joined hands with Johns Hopkins. AHEL singed the Joint Venture Agreement with Deutsche Krankenversicherung AG (DKV) for setting up the Health Insurance Business in October 11 of the year 2006. AHEL had signed an agreement with Cadila Pharmaceuticals Limited as a partner in Apollo Hospitals International Limited, Ahmedabad. Also in the year the hospital had acquired the Zavata. The week magazine rated the Apollo Hospitals as the Best Private Sector Hospital in India for the year 2006. As at June 15th 2007, AHEL launched Health City, the first of its kind in Asia, at Hyderabad, an integrated healthcare delivery facility, spread over 33 acres, to cover disease prevention, management, wellness and research.

As at January 2008, the hospital has signed an agreement with Hindustan Construction Co (HCC), a real estate firm, to set up the medicity inside the upcoming hill station named Lavasa in Maharashtra. With an eye on foreign patients, Apollo Hospitals is setting up a medicity near Pune that will offer 'first rate ayurveda treatment'. The Apollo and BAI Medical Centre Ltd, a subsidiary of British American Investment Co (Mtius) Ltd Made a JV in February of the year 2008 to set up a hospital in Mauritius.

Apollo Hospitals Enterprise Ltd (AHEL) and Quintiles Mauritius Holdings Inc., (Quintiles) entered into a Shareholders Agreement on 27 January 2009 for setting up a Phase I clinical trial research facility in Hyderabad at an estimated cost of USD 6 million, through a separate joint venture company to be formed for this purpose. Quintiles and AHEL will be funding the project cost in the ratio of 60-40 respectively through a combination of debt and/or equity.

The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 28 January 2010 approved the allotment of 1,500 Unsecured Foreign Currency Convertible Bonds (FCCB) of face value of USD 10,000 each aggregating to US$ 15 million with an option of convertible into equity shares at a price of Rs 605 per share to International Finance Corporation, Washington.

The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 28 May 2010 approved the sub-division of each existing equity share of nominal value of Rs 10 each into 2 equity shares of nominal value of Rs 5 each.

The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 9 December 2010 approved the allotment of 11.40 lakh equity shares to International Finance Corporation, Washington on conversion of Foreign Currency Convertible Bonds to the extent of US$ 7.50 million. These shares have been issued at a price of Rs 302.50 per share at a premium of 14% over the floor price determined as per the FCCB Scheme, 1993 (after the subdivision of each equity share of face value of Rs. 10/- per share into two equity shares of face value of Rs. 5/- each) and in accordance with the terms of the FCCB Loan Agreement dated 18 June 2009.

On 18 July 2011, Apollo Hospitals Enterprise closed qualified institutional placement of equity shares. The company will issue 66.66 lakh equity shares at a price of Rs 495 per share to qualified institutional buyers for an amount aggregating Rs 330 crore.

On 7 June 2012, Apollo Hospitals Enterprise announced that International Finance Corporation (IFC), Washington had sent a communication to the company requesting for conversion of the balance loan amount of USD 7.50 million of the Foreign Currency Convertible Bonds (FCCBs) into equity shares. In this regard, committee of the Board of Directors at its meeting held on 7 June 2012 approved the allotment of 13.81 lakh equity shares to International Finance Corporation, Washington.

On 10 December 2012, Apollo Hospitals Enterprise announced that it has signed a definitive agreement with Sutherland Global Services, a global provider of business process and technology management services, to enable Sutherland Global Services acquire 100% of the shares of Apollo Health Street Limited (AHS), a leading provider of healthcare business services and world-class Health Information Technology (HIT) based solutions. AHS is an associate company of Apollo Hospitals Enterprise. This acquisition will position the combined organization as a leading healthcare service provider with comprehensive information technology and business process integrated solutions and consolidate its presence as a dominant player in the $38 billion US healthcare business process outsourcing (BPO). This also fosters Apollo Hospitals' strategic intent of focusing and growing its core healthcare delivery services.

On 21 January 2013, Apollo Hospitals Enterprise announced its plans to establish a Proton Therapy Center in India, the first of its kind across South East Asia, Africa and Australia. This launch that marks the beginning of the next wave of advancement in radiation therapy in India is worth approximately Rs 400 crore, which covers the equipment and services supplied by IBA (Ion Beam Applications S.A.) to help establish the Apollo Proton Therapy Center including the long-term operation and maintenance contract.

On 17 September 2014, Apollo Hospitals Enterprise announced that it has entered into an MoU with Hetero Med Solutions Limited (HMSL) for the acquisition of its retail pharmacy stores currently operated in Telengana, Andhra Pradesh and Tamilnadu. The acquisition would be in the form of purchase of the business undertaking, on a slump sale basis and comprises of 320 pharmacy stores, at an overall consideration not exceeding Rs 146 crore. This acquisition will further strengthen Apollo Pharmacy's leadership position in the industry. The addition of 320 stores are in existing core geographies where Apollo Pharmacy has a strong market presence and further consolidate its presence as a significant player in this region. Apollo Pharmacy plans to leverage its existing backend infrastructure to drive economies of scale, thereby accelerating profitability for these stores. This will also create an opportunity to increase the sales of Apollo private label products.

Apollo Health and Lifestyle Limited (AHLL), a wholly owned subsidiary of Apollo Hospitals Enterprise, announced on 30 January 2014 that Sanofi-Synthelabo (India) Limited has invested into Apollo Sugar Clinics Limited (ASCL). ASCL is a disease management clinic focused on providing high quality, integrated care across its clinics for people with diabetes. An amount of Rs 90 crore is being invested by Sanofi-Synthelabo in this venture through a combination of primary and secondary funding. Earlier, on 30 September 2014, Apollo Hospitals Enterprise and Sanofi announced their decision to collaborate on the expansion of Apollo Sugar Clinics.

On 6 January 2015, Apollo Health and Lifestyle Limited (AHLL), a wholly owned subsidiary of Apollo Hospitals Enterprise, announced that it has successfully completed the acquisition of Nova Specialty Hospitals. The deal size would be in the range of Rs 135-145 crore. Nova Specialty Hospitals' existing centres will serve as new centres under the Apollo brand name. The acquired chain of Nova Specialty Hospitals is spread over 8 cities and will add to the Apollo network 45 Modular OTs, over 350 patient beds, with an average 20,000 SFT of built-up space in each centre. These centres provide both In-patient and OPD services with 60% of the procedures currently being done as day procedures.

The Board of Directors of Apollo Energy Company Ltd., an Apollo Hospitals Group Company, at its meeting held on 25 January 2016 approved the divestment of 23.3% shareholding in Apollo Munich Health Insurance Company Ltd. (Apollo Munich) to its joint venture partner, Munich Re of Germany for Rs 163.5 crore. Post consummation of the transaction, Apollo Hospitals Group's shareholding in Apollo Munich shall stand reduced from 74.4% to 51.1%. Correspondingly, Munich Re's shareholding in Apollo Munich shall increase to 48.7% and 0.2% stake will be held by employees. Apollo Hospitals shall continue to hold its stake in Apollo Munich. Apollo Munich Health Insurance is one of the largest private sector health insurance companies offering comprehensive health insurance plans for individuals, families, senior citizens and corporates.

On 12 March 2016, Apollo Hospitals Enterprise announced that it has completed the acquisition of 51% majority stake in Assam Hospitals Limited, Guwahati for a cash consideration of Rs 57.25 crore which will be utilized for refurbishing the hospital including addition of new equipments as well as towards expansion of the existing hospital block. Assam Hospitals Limited which was incorporated in 1997 and commenced operations from 1999, is engaged in the business of healthcare services. It has a presence in Guwahati where it currently runs a 220 bed hospital facility. The objective of the acquisition is to strengthen Apollo Hospitals leadership position in the hospital space as well as enhance its presence in North eastern region where it already has strong brand equity.

On 20 June 2016, Apollo Hospitals Enterprise and Hainan Ecological Smart City Group (HESCG), China signed a Memorandum of Understanding (MoU) to build a state-of-the art hospital in Hainan Province, China. HESCG will provide land, all investments for the construction, commissioning and equipping the hospital besides all operative expenses, while Apollo Hospitals Group would provide its services technical consulting, planning and commissioning of the hospital and post completion of the hospital, provide services for the operations and management of the hospital. Apollo Hospitals would also support in building the technical and management personnel, install it's acclaimed patient care clinical protocols and practices.

The Board of Directors of Apollo Hospitals Enterprise at its meeting held on 1 September 2016 discussed and deliberated the possibility of considering and evaluating various options to restructure and reorganize the businesses of the company, by re-aligning the business lines as per verticals. The proposal for such restructuring is aimed at exploring options for improving operational efficiencies and augmenting further growth of the businesses in compliances with the applicable laws and creating greater flexibility through such restructuring and/or transfer of the existing businesses into separate legal entities, given the large opportunity that exits in the healthcare sector.

On 1 December 2016, Apollo Hospitals Enterprise announced that International Finance Corporation (affiliated to the World Bank) along with associated entity, has made a primary equity infusion of Rs 450 crore thereby acquiring a 29.03% stake in Apollo Health and Lifestyle Limited (AHLL), earlier a wholly owned subsidiary of the company. The equity infusion will be utilized to finance AHLL's growth plans. AHLL is engaged in retail healthcare business encompassing primary health clinics, birthing centres, dental & dialysis centres, day surgery centres and sugar clinics.

During the FY2017, the company has allotted 2000 Non Convertible Debentures of face value of Rs 1 million each to HDFC Bank Limited, 2,500 Non Convertible Debenture of face value of Rs 1 million each to Yes Bank Limited and 500 Non Convertible Debenture of face value of Rs 1 million each to Birla Sun Life Insurance Company Limited.

The Company had reduced its equity stake to 40% from 100% in Apollo Healthcare Technology Solutions Limited (AHTSL) on 23rd January 2017. However AHTSL shall continue to be a subsidiary of the Company due to the definition of controlling interest between the companies as per Ind AS standards.

One multi-speciality hospital at Navi, Mumbai was inaugurated during the year 2016-17.

As on 31st March 2017, your Company had eighteen direct subsidiaries, four step down subsidiaries, three joint ventures, and four associate companies.

During the FY2017,Apollo Hospital International Limited and Future Parking Private Limited have become the subsidiaries of the company.

During the year, Apollo Hospitals, Chennai and Indraprastha Apollo Hospitals, New Delhi were awarded the top 2 positions in the All India Critical Care Hospital Survey 2017 by Times Health.

As on 31st March 2019, the Company had nineteen direct subsidiaries, ten step down subsidiaries, four joint ventures and four associate companies.

The Board of Directors at their meeting held on November 14, 2018 have approved a Scheme of Arrangement ('the Scheme') between Apollo Hospitals Enterprise Limited ('AHEL') and Apollo Pharmacies Limited ('APL') and their respective shareholders in accordance with the provisions of Sections 230 to 232 of the Companies Act, 2013, for the transfer of the front-end retail pharmacy business ('the disposal group') carried out in the standalone pharmacy segment to APL by way of slump sale, subject to necessary approvals by stock exchanges, shareholders, National Company Law Tribunal and all other requisite regulatory authorities.

Pursuant to the Scheme of Arrangement (the Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT) vide order dated August 3, 2020, with effect from April 1, 2019 (Appointed date'), the front-end retail pharmacy included in the standalone pharmacy segmentis transferred to Apollo Pharmacies Limited ('APL'), a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs.52,780 lakhs. In accordance with Section 230 of the Companies Act, the Company filed the NCLT order with the Ministry of Company Affairs (Registrar of Companies) on September 1, 2020. Consequentto the filing, the Scheme became effective from September 1, 2020 (effective date').

The Company holds 25.5% of the equity shares in AMPL as on the effective date.

The Board of Directors at their meeting held on February 13, 2020 had approved the amalgamation of Apollo Home Healthcare (India) Limited and Western Hospitals Corporation Private Limited, wholly owned subsidiaries of the Company ('Transferor Companies') into Apollo Hospitals Enterprise Limited (Transferee Company) by way of a Scheme of Amalgamation between the Transferor Companies and the Transferee Company and their respective shareholders and creditors, in accordance with Sections 230 to 234 of the Companies Act, 2013.

The amalgamation is subject to requisite statutory and regulatory approvals and sanction by the respective shareholders of each of the companies involved in the scheme. There will not be any change in the shareholding pattern of the Transferee Company pursuant to implementation of the Scheme of Amalgamation as the Transferor Companies are wholly owned subsidiaries of the Transferee Company.

During the FY2020, Apollo Healthcare Technology Solutions Limited, a subsidiary of the Company had applied for strike off of its name to the Registrar of Companies on 19th March 2020.

The Company had divested its entire equity stake in Apollo Munich Health Insurance Company Ltd (AMHIL) on 9th January 2020 and consequently. AMHIL has ceased to be an Associate Company.

As on 31st March 2020, Company had 18 direct subsidiaries, 10 step down subsidiaries, 4 joint ventures and 3 associate companies.

As on 31 March 2020, AHEL had a network of 71 hospitals with total bed capacity of 10261.

The Board of Directors, in their meeting held on November 11, 2020 have approved the proposal for executing a definitive Share Purchase Agreement (SPA) for the acquisition of 50% equity stake held by Gleneagles Development PTE Limited, Singapore, in Apollo Gleneagles Hospital Limited, Kolkata ('AGHL'), a joint venture in which the Company holds a 50% equity stake, for a cash consideration of Rs 41,000 lakhs.

The Company had 18 direct subsidiaries, 10 step down subsidiaries, 4 joint ventures and 4 associate companies as on 31 March, 2021.

The company completed a QIP in January 2021,allotting an additional 4659498 equity shares at a price of Rs 2511 per share (premium of Rs 2506 per share) aggregating to a sum of Rs 116999.99 lakhs.

The Scheme of Arrangement relating to transfer of front end portion of retail pharmacy business (divestment business) to Apollo Pharmacies Limited (APL or Transferee Company) , a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs. 5,278 million was approved by the National Company Law Tribunal vide their order dated August 3, 2020.
Pursuant to the Scheme becoming effective from 1st September, 2020, the Company invested a sum of Rs. 365 million towards its share of equity contribution and its ownership interest in AMPL reduced to 25.50% .

On 07 January 2021, the company acquired 1% additional stake in Medics International Life Sciences Limited, a Joint Venture,which runs a 330-bedded hospital in Lucknow. Consequently Medics became the subsidiary of the Company.

During year 2021, Company acquired the entire equity stake held by the existing shareholders in Apollo Health Co Limited (AHL) on 23rd June 2021. Consequent to that, AHL became a wholly owned subsidiary to the Company.

The Company had received approval on June 28, 2021 for Scheme of Amalgamation with the wholly owned subsidiary companies, Apollo Home Healthcare (India) Limited (AHHCL) and Western Hospitals Corporation Private Limited (WHCPL). The Appointed Date for the Scheme was 1st April, 2020 and the entire assets and liabilities of AHHCL and WHCPL got transferred to and recorded by Company. The entire share capital of AHHCL and WHCPL held by Company, stood cancelled without any further act or deed and no consideration was issued upon the amalgamation coming into effect.

As on 31st March 2022, the Company had 18 direct subsidiaries, 12 step down subsidiaries, 2 joint ventures and 3 associate companies.

The Board of Directors, in their meeting held on November 11, 2020 acquired 50% equity stake held by Gleneagles Development Pte Ltd., Singapore in AMSHL, in which the Company held a 50% equity stake at a consideration of Rs. 4,100 million. The Company acquired 50% equity stake held in AMSHL by Gleneagles Development Pte Limited on 22nd April, 2021. Consequently, AMSHL became a wholly-owned subsidiary of the Company effective from April 22, 2021, and name of the Company was changed from Apollo Gleneagles Hospital Limited to Apollo Multispeciality Hospitals Limited based on the approval obtained from the Ministry of Corporate Affairs on 5th May, 2021.

Effective 16th March 2022, the Pharmacy Distribution business along with the Omni channel digital healthcare platform Apollo 24/7 and the Company's equity interest in Apollo Medical Private Limited was transferred to Apollo HealthCo Limited
which is a wholly owned subsidiary of AHEL, through a slump sale process for a net consideration of Rs. 12,100 million.

As of March 31, 2022 the Company had a capacity of 9,911 beds in 71 hospitals located in India and overseas. Of the 9,911 beds, 8,538 beds are located in 44 owned hospitals, 278 beds in 11 cradles, 244 beds in 11 day care/ short surgical stay centers and 851 beds are in 5 hospitals under their management through operations and management contracts.

During 2022-23, the Company acquired a 60% equity stake in Kerala First Health Services Private Limited (KFHSL), for a consideration costing Rs 26.4 Crores and consequently, KFHSL became a subsidiary of the Company.

As of March 31, 2023, Company had a capacity of 9,957 beds in 70 hospitals located in India and overseas. Of the 9,957 beds, 8,544 beds are located in 43 owned hospitals, 305 beds in 11 cradles, 257 beds in 11 day care/ short surgical stay centers and 851 beds are in 5 hospitals operated through operations and management contracts. The Apollo Proton Cancer Center was opened in Chennai in FY'23.

As of March 31, 2024 Company had a capacity of 10,134 beds in 73 hospitals located in India and overseas. Of the 10,134 beds, 8,710 beds are located in 45 owned hospitals, 363 beds in 11 cradles, 271 beds in 11 day care/ short surgical stay centers and 790 beds are in 6 hospitals
under their management through operations and management contracts. Apollo Hospitals, Bengaluru, launched India's first AI-Precision Oncology Centre (AI-POC) in 2024. Apollo Hospitals unveiled the ZAP-X Gyroscopic Radiosurgery Platform, a revolutionary advancement in brain tumor treatment, marking a significant milestone as the first in South Asia to introduce this ground-breaking technology. The Company has launched India's first Comprehensive Connected Care Services in 2024. Apollomedics Super Specialty Hospital, Lucknow launched Artificial Intelligence powered Robotic Knee Replacement Surgery services. Apollo acquired the latest BK500 Ultrasound system for cancer detection, implementing the latest procedure known as Trans-Perineal Real Time Fusion (TP RTF) prostate biopsy. Apollo Multi-specialty Hospitals, Kolkata acquired the Da Vinci Xi Robot as a first for eastern India.

Parent organization Pratap Reddy
NSE symbol APOLLOHOSP
Founded 1979
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Apollo Hospitals Enterprise Ltd?

Answer Field

The share price of Apollo Hospitals Enterprise Ltd for NSE is ₹ 6977 and for BSE is ₹ 6954.05.

What is the Market Cap of Apollo Hospitals Enterprise Ltd?

Answer Field

The market cap of Apollo Hospitals Enterprise Ltd for NSE is ₹ 10,03,18.60 Cr. and for BSE is ₹ 9,99,88.56 Cr. as of now.

What is the 52 Week High and Low of Apollo Hospitals Enterprise Ltd?

Answer Field

The 52 Week High and Low of Apollo Hospitals Enterprise Ltd for NSE is ₹ 7545.35 and ₹ 5693.20 and for BSE is ₹ 7545.10 and ₹ 5690.80.

How to Buy Apollo Hospitals Enterprise Ltd share?

Answer Field

You can trade in Apollo Hospitals Enterprise Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Apollo Hospitals Enterprise Ltd?

Answer Field

The 1 year returns on the stock has been 17.31%.

What is the Current Share Price of Apollo Hospitals Enterprise Ltd?

Answer Field

Apollo Hospitals Enterprise Ltd share price is for NSE ₹ 6977 & for BSE ₹ 6954.05 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Apollo Hospitals Enterprise Ltd Share?

Answer Field

The market cap of Apollo Hospitals Enterprise Ltd for NSE ₹ 10,03,18.60 & for BSE ₹ 9,99,88.56 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Apollo Hospitals Enterprise Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Apollo Hospitals Enterprise Ltd share is 83.30.

What is the PB ratio of Apollo Hospitals Enterprise Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Apollo Hospitals Enterprise Ltd share is 569.62.

How to Buy Apollo Hospitals Enterprise Ltd Share?

Answer Field

You can trade in Apollo Hospitals Enterprise Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Apollo Hospitals Enterprise Ltd Share on Bajaj Broking App?

Answer Field

To buy Apollo Hospitals Enterprise Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Apollo Hospitals Enterprise Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Apollo Hospitals Enterprise Ltd?

Answer Field

The CEO of Apollo Hospitals Enterprise Ltd is Dr Madhu Sasidhar.

When was Apollo Hospitals Enterprise Ltd established?

Answer Field

The company was established on 18 September 1983.

What factors influence the Apollo Hospitals Share Price?

Answer Field

Factors like the company’s expansion strategy, profit and revenue growth, and international patients have a great impact on the Apollo Hospitals Share Price.

Is Apollo Hospitals Enterprise Ltd debt-free?

Answer Field

No, the company is not debt-free.

What is the CAGR of Apollo Hospitals Share?

Answer Field

The company's CAGR for the past 5 years stands between 26.3% and 63.8%.

How has the Apollo Hospitals Share Price performed over the past year?

Answer Field

Apollo Hospital’s operating income fell by 0.2% YoY, while its operating profit grew by 55.7% YoY. The net profit of the company also saw a growth of 61.6% YoY, and its net profit margins grew from 13.9% in FY23 to 22.5% in FY24.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|